Top

Journal of Neuroinflammation

Published in:

Open Access 01-12-2012 | Research

Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation

Authors: Deepak Kumar Kaushik, Rupanjan Mukhopadhyay, Kanhaiya Lal Kumawat, Malvika Gupta, Anirban Basu

Published in: Journal of Neuroinflammation | Issue 1/2012

Abstract

Background

Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4.

Methods

For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500 ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1 expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4, cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different conditions.

Results

Our findings suggest that honokiol can substantially downregulate the production of proinflammatory cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol.

Conclusions

Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner.

Carson MJ, Thrash JC, Lo D: Analysis of microglial gene expression: identifying targets for CNS neurodegenerative and autoimmune disease. Am J Pharmacogenomics 2004, 4:321–330.CrossRefPubMed

Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312–318.CrossRefPubMed

Lund S, Christensen KV, Hedtjarn M, Mortensen AL, Hagberg H, Falsig J, Hasseldam H, Schrattenholz A, Porzgen P, Leist M: The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 2006, 180:71–87.CrossRefPubMed

Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453–462.CrossRefPubMedPubMedCentral

Rhee SH, Hwang D: Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem 2000, 275:34035–34040.CrossRefPubMed

Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001, 480–481:243–268.CrossRefPubMed

Brown GC, Neher JJ: Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010, 41:242–247.CrossRefPubMed

Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193–201.CrossRefPubMed

Carson MJ: Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 2002, 40:218–231.CrossRefPubMedPubMedCentral

10.

Kim YS, Joh TH: Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 2006, 38:333–347.CrossRefPubMed

11.

Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK: Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem 2007, 282:13769–13779.CrossRefPubMed

12.

Feinberg MW, Cao Z, Wara AK, Lebedeva MA, Senbanerjee S, Jain MK: Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem 2005, 280:38247–38258.CrossRefPubMed

13.

Yoon HS, Chen X, Yang VW: Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem 2003, 278:2101–2105.CrossRefPubMed

14.

Liu J, Liu Y, Zhang H, Chen G, Wang K, Xiao X: KLF4 promotes the expression, translocation, and release of HMGB1 in RAW264.7 macrophages in response to LPS. Shock 2008, 30:260–266.PubMed

15.

Shen B, Smith RS Jr, Hsu YT, Chao L, Chao J: Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem 2009, 284:35471–35478.CrossRefPubMedPubMedCentral

16.

Alder JK, Georgantas RW, Hildreth RL, Kaplan IM, Morisot S, Yu X, McDevitt M, Civin CI: Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol 2008, 180:5645–5652.CrossRefPubMedPubMedCentral

17.

Segre JA, Bauer C, Fuchs E: Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet 1999, 22:356–360.CrossRefPubMed

18.

Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW, Kaestner KH: The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 2002, 129:2619–2628.PubMedPubMedCentral

19.

Kaushik DK, Gupta M, Das S, Basu A: Kruppel-like factor 4, a novel transcription factor regulates microglial activation and subsequent neuroinflammation. J Neuroinflammation 2010, 7:68.CrossRefPubMedPubMedCentral

20.

Shen CC, Ni CL, Shen YC, Huang YL, Kuo CH, Wu TS, Chen CC: Phenolic constituents from the stem bark of Magnolia officinalis. J Nat Prod 2009, 72:168–171.CrossRefPubMed

21.

Lin YR, Chen HH, Ko CH, Chan MH: Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 2006, 537:64–69.CrossRefPubMed

22.

Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, Zhao X, Wei Y, Chen L: Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9 L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 2011, 6:e18490.CrossRefPubMedPubMedCentral

23.

Fried LE, Arbiser JL: Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 2009, 11:1139–1148.CrossRefPubMedPubMedCentral

24.

Lin YR, Chen HH, Ko CH, Chan MH: Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007, 81:1071–1078.CrossRefPubMed

25.

Lee SY, Cho JY: Inhibitory effects of honokiol on LPS and PMA-induced cellular responses of macrophages and monocytes. BMB Rep 2009, 42:574–579.CrossRefPubMed

26.

Li CY, Chao LK, Wang SC, Chang HZ, Tsai ML, Fang SH, Liao PC, Ho CL, Chen ST, Cheng WC, Chiang CS, Kuo YH, Hua KF, Hsu IC: Honokiol inhibits LPS-induced maturation and inflammatory response of human monocyte-derived dendritic cells. J Cell Physiol 2011, 226:2338–2349.CrossRefPubMed

27.

Chao LK, Liao PC, Ho CL, Wang EI, Chuang CC, Chiu HW, Hung LB, Hua KF: Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem 2011, 58:3472–3478.CrossRef

28.

Weng TI, Wu HY, Kuo CW, Liu SH: Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation. Intensive Care Med 2011, 37:533–541.CrossRefPubMed

29.

Li J, Shao X, Wu L, Feng T, Jin C, Fang M, Wu N, Yao H: Honokiol: an effective inhibitor of tumor necrosis factor-alpha-induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts. Acta Biochim Biophys Sin (Shanghai) 2011, 43:380–386.CrossRef

30.

Wu F, Zhang W, Li L, Zheng F, Shao X, Zhou J, Li H: Inhibitory effects of honokiol on lipopolysaccharide-induced cellular responses and signaling events in human renal mesangial cells. Eur J Pharmacol 2011, 654:117–121.CrossRefPubMed

31.

Munroe ME, Businga TR, Kline JN, Bishop GA: Anti-inflammatory effects of the neurotransmitter agonist honokiol in a mouse model of allergic asthma. J Immunol 2010, 185:5586–5597.CrossRefPubMedPubMedCentral

32.

Chiang CK, Sheu ML, Hung KY, Wu KD, Liu SH: Honokiol, a small molecular weight natural product, alleviates experimental mesangial proliferative glomerulonephritis. Kidney Int 2006, 70:682–689.CrossRefPubMed

33.

Mishra MK, Ghosh D, Duseja R, Basu A: Antioxidant potential of minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 2009, 54:464–470.CrossRefPubMed

34.

Perrella MA, Patterson C, Tan L, Yet SF, Hsieh CM, Yoshizumi M, Lee ME: Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells. Evidence for mechanisms other than NF-kappaB. J Biol Chem 1996, 271:13776–13780.CrossRefPubMed

35.

Pathak SK, Bhattacharyya A, Pathak S, Basak C, Mandal D, Kundu M, Basu J: Toll-like receptor 2 and mitogen- and stress-activated kinase 1 are effectors of Mycobacterium avium -induced cyclooxygenase-2 expression in macrophages. J Biol Chem 2004, 279:55127–55136.CrossRefPubMed

36.

Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A: Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007, 55:483–496.CrossRefPubMed

37.

Eugenin EA, Berman JW: Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003, 29:351–361.CrossRefPubMed

38.

Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1–78.CrossRefPubMed

39.

Kishimoto T: Interleukin-6 and its receptor in autoimmunity. J Autoimmun 1992,5(Suppl A):123–132.CrossRefPubMed

40.

Chen CM, Liu SH, Lin-Shiau SY: Honokiol, a neuroprotectant against mouse cerebral ischaemia, mediated by preserving Na+, K + -ATPase activity and mitochondrial functions. Basic Clin Pharmacol Toxicol 2007, 101:108–116.CrossRefPubMed

41.

Brown GC, Cooper CE: Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 1994, 356:295–298.CrossRefPubMed

42.

Iadecola C, Zhang F: Permissive and obligatory roles of NO in cerebrovascular responses to hypercapnia and acetylcholine. Am J Physiol 1996, 271:R990-R1001.PubMed

43.

Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1996, 1299:125–140.CrossRefPubMed

44.

Mestre JR, Mackrell PJ, Rivadeneira DE, Stapleton PP, Tanabe T, Daly JM: Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells. J Biol Chem 2001, 276:3977–3982.CrossRefPubMed

45.

Caivano M, Cohen P: Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 2000, 164:3018–3025.CrossRefPubMed

46.

Shen S, Yu S, Binek J, Chalimoniuk M, Zhang X, Lo SC, Hannink M, Wu J, Fritsche K, Donato R, Sun GY: Distinct signaling pathways for induction of type II NOS by IFNgamma and LPS in BV-2 microglial cells. Neurochem Int 2005, 47:298–307.CrossRefPubMed

47.

Kim BH, Cho JY: Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol Sin 2008, 29:113–122.CrossRefPubMed

48.

Matsuda H, Kageura T, Oda M, Morikawa T, Sakamoto Y, Yoshikawa M: Effects of constituents from the bark of Magnolia obovata on nitric oxide production in lipopolysaccharide-activated macrophages. Chem Pharm Bull(Tokyo) 2001, 49:716–720.CrossRef

49.

Kim KR, Park KK, Chun KS, Chung WY: Honokiol inhibits the progression of collagen-induced arthritis by reducing levels of pro-inflammatory cytokines and matrix metalloproteinases and blocking oxidative tissue damage. J Pharmacol Sci 2010, 114:69–78.CrossRefPubMed

50.

Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 2003, 475:19–27.CrossRefPubMed

51.

Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res 2003, 992:159–166.CrossRefPubMed

52.

Cui HS, Huang LS, Sok DE, Shin J, Kwon BM, Youn UJ, Bae K: Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA. Phytomedicine 2007, 14:696–700.CrossRefPubMed

Title: Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
Authors: Deepak Kumar Kaushik
Rupanjan Mukhopadhyay
Kanhaiya Lal Kumawat
Malvika Gupta
Anirban Basu
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/1742-2094-9-57

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study

Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden

Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways

Acute injury in the peripheral nervous system triggers an alternative macrophage response

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study